ReviewHNO2025
[Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].
Review in HNO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucagon-like peptide‑1 receptor agonists (GLP‑1 RA), such as semaglutide and tirzepatide were originally developed for treatment of type 2 diabetes and have shown significant weight loss effects. This has led to increasing off-label use for esthetic weight reduction. The associated facial changes, particularly volume loss, skin laxity and increased wrinkle formation, are gaining attention in plastic esthetic medicine.
objectiveThis study reviews the current literature on GLP‑1 RAs, their esthetic effects and potential therapeutic approaches.
methodsA selective literature review on GLP‑1 RAs was conducted, focusing on mechanisms of action, clinical effects, off-label use, esthetic consequences and treatment options.
resultsThe use of GLP‑1 RAs promotes weight loss by regulating appetite and delaying gastric emptying. Frequent side effects include gastrointestinal symptoms, such as nausea, vomiting, diarrhea or obstipation. A possible association with thyroid tumors remains unclear. The increasing off-label use has led to supply shortages in some regions. Esthetic changes, termed "Ozempic face", include volume loss, skin laxity and pronounced wrinkles. Treatment options discussed in the literature include noninvasive (high-intensity focused ultrasound, HIFU, radiofrequency), minimally invasive (fillers, biostimulators) and surgical procedures (facelifting, fat grafting).
conclusionThe rising off-label use of GLP‑1 RAs presents new challenges for esthetic medicine. Rapid fat loss results in pronounced facial changes, driving demand for corrective interventions; however, systematic studies on the effectiveness and safety of this treatment are lacking. Further research is needed to develop evidence-based strategies and standardized guidelines for the esthetic management of affected patients.
Indexed as
Identifiers
40767957What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.